1. The aurora kinase inhibitor VX-680 shows anti-cancer effects in primary metastatic cells and the SW13 cell line

   • Raffaele Pezzani
   • Beatrice Rubin
   • Marco Boscaro

   PRECLINICAL STUDIES 14 May 2016 Pages: 531 - 540

   

2. In vitro and in vivo antineoplastic and immunological effects of pterocarpanquinone LQB-118

   • Eduardo J. Salustiano
   • Matheus L. Dumas
   • Vivian M. Rumjanek

   PRECLINICAL STUDIES 18 May 2016 Pages: 541 - 551

   

3. Molecular and cellular effects of a novel hydroxamate-based HDAC inhibitor – belinostat – in glioblastoma cell lines: a preliminary report

   • Magdalena Kusaczuk
   • Rafał Krętowski
   • Marzanna Cechowska-Pasko

   PRECLINICAL STUDIES Open access 29 July 2016 Pages: 552 - 564

   

4. Pharmacokinetics and excretion of ¹⁴C-omacetaxine in patients with advanced solid tumors

   • Cynthia M. Nijenhuis
   • Edward Hellriegel
   • Jan H. M. Schellens

   PHASE I STUDIES Open access 25 May 2016 Pages: 565 - 574

   

5. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001)

   • Amy Prawira
   • Irene Brana-Garcia
   • Aaron R Hansen

   PHASE I STUDIES 11 June 2016 Pages: 575 - 583

   

6. A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies

   • Kiyotaka Yoh
   • Toshihiko Doi
   • Kazunori Uenaka

   PHASE I STUDIES Open access 01 September 2016 Pages: 584 - 595

   

7. Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors

   • Hidenori Mizugaki
   • Noboru Yamamoto
   • Toshiaki Takahashi

   PHASE I STUDIES Open access 01 July 2016 Pages: 596 - 603

   

8. A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors

   • Lee S. Rosen
   • Patricia LoRusso
   • Branimir I. Sikic

   PHASE I STUDIES 16 July 2016 Pages: 604 - 613

   

9. A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia

   • Karen W. L. Yee
   • Hsiao-Wei T. Chen
   • Mark D. Minden

   PHASE I STUDIES 12 July 2016 Pages: 614 - 624

   

10. Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer

    • Giorgio Scagliotti
    • Jin Hyoung Kang
    • Mary Pinder-Schenck

    PHASE II STUDIES 27 June 2016 Pages: 625 - 635

    

11. Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites

    • Naminatsu Takahara
    • Hiroyuki Isayama
    • Kazuhiko Koike

    PHASE II STUDIES 23 June 2016 Pages: 636 - 642

    

12. The renal effects of ALK inhibitors

    • Hassan Izzedine
    • Rania Kheder El-Fekih
    • Mark A. Perazella

    REVIEW 29 July 2016 Pages: 643 - 649

13. Intravitreal vascular endothelial growth factor (VEGF) inhibitor injection in unrecognised early pregnancy

    • Farzan Kianersi
    • Heshmatollah Ghanbari
    • Afsaneh Naderi Beni

    SHORT REPORT 02 June 2016 Pages: 650 - 653

14. Prediction of response to everolimus in neuroendocrine tumors: evaluation of clinical, biological and histological factors

    • Noura Benslama
    • Julien Bollard
    • Thomas Walter

    SHORT REPORT 26 May 2016 Pages: 654 - 662

    

15. Involvement of AMP-activated protein kinase in mediating pyrrolo-1,5-benzoxazepine–induced apoptosis in neuroblastoma cells

    • Jennifer C. Lennon
    • Stefania Butini
    • Daniela M. Zisterer

    SHORT REPORT 22 June 2016 Pages: 663 - 676